MLL successfully represented AstraZeneca in patent infringement proceedings against Sandoz before the Swiss Federal Patent Court


MLL represented the patent proprietor AstraZeneca in patent infringement proceedings against Sandoz, concerning AstraZeneca’s fulvestrant formulation patent. The Federal Patent Court decided that AstraZeneca’s patent was valid and infringed by Sandoz’s generic product.

The fulvestrant formulation, marketed by AstraZeneca under the name Faslodex®, is used to treat breast cancer by intramuscular injection.

The litigation team was composed of MLL’s attorneys-at-law Michael Ritscher (Head of IP) and Kilian Schärli (partner) as well as European Patent Attorney Thorsten Bausch (partner at Hoffmann Eitle) and MLL’s European Patent Attorney Ulrike Ciesla (partner).